MX2024007862A - Una composicion farmaceutica inyectable para el tratamiento de enfermedades respiratorias en animales. - Google Patents

Una composicion farmaceutica inyectable para el tratamiento de enfermedades respiratorias en animales.

Info

Publication number
MX2024007862A
MX2024007862A MX2024007862A MX2024007862A MX2024007862A MX 2024007862 A MX2024007862 A MX 2024007862A MX 2024007862 A MX2024007862 A MX 2024007862A MX 2024007862 A MX2024007862 A MX 2024007862A MX 2024007862 A MX2024007862 A MX 2024007862A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
injectable pharmaceutical
animals
treatment
respiratory diseases
Prior art date
Application number
MX2024007862A
Other languages
English (en)
Spanish (es)
Inventor
Thorsten Meyer
Ralf Warrass
Joachim Ullrich
Chen - Chao Wang
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2024007862A publication Critical patent/MX2024007862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2024007862A 2021-12-24 2022-12-23 Una composicion farmaceutica inyectable para el tratamiento de enfermedades respiratorias en animales. MX2024007862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21217704 2021-12-24
PCT/EP2022/087700 WO2023118557A1 (en) 2021-12-24 2022-12-23 An injectable pharmaceutical composition for the treatment of respiratory diseases in animals

Publications (1)

Publication Number Publication Date
MX2024007862A true MX2024007862A (es) 2024-07-09

Family

ID=79601675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007862A MX2024007862A (es) 2021-12-24 2022-12-23 Una composicion farmaceutica inyectable para el tratamiento de enfermedades respiratorias en animales.

Country Status (9)

Country Link
US (1) US20250057790A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452226A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024544415A (cg-RX-API-DMAC7.html)
CN (1) CN118632684A (cg-RX-API-DMAC7.html)
AR (1) AR128074A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022420882A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242451A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007862A (cg-RX-API-DMAC7.html)
WO (1) WO2023118557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
AR134777A1 (es) 2023-12-21 2026-04-01 Intervet Int Bv Formas cristalinas de sales de (s)-n-(3-amino-1-(hidroxiamino)-3-metil-1-oxobutan-2-il)-4-((4-(((2-metoxietil)amino)metil)fenil)etinil)benzamida
CN122422289A (zh) 2023-12-21 2026-07-17 英特维特国际股份有限公司 (s)-n-(3-氨基-1-(羟基氨基)-3-甲基-1-氧代丁-2-基)-4-((4-(((2-甲氧基乙基)氨基)甲基)苯基)乙炔基)苯甲酰胺盐的结晶形式的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
JP7082445B2 (ja) 2016-12-23 2022-06-08 インターベット インターナショナル ベー. フェー. ウシ又はブタの呼吸器疾患を治療するための化合物

Also Published As

Publication number Publication date
CA3242451A1 (en) 2023-06-29
WO2023118557A1 (en) 2023-06-29
US20250057790A1 (en) 2025-02-20
AU2022420882A1 (en) 2024-06-20
JP2024544415A (ja) 2024-11-29
EP4452226A1 (en) 2024-10-30
AR128074A1 (es) 2024-03-20
CN118632684A (zh) 2024-09-10

Similar Documents

Publication Publication Date Title
CA3242451A1 (en) An injectable pharmaceutical composition for the treatment of respiratory diseases in animals
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
BRPI0618374A2 (pt) uso de um composto ou um derivado do mesmo farmaceuticamente aceitável, métodos para matar microorganismos clinicamente latentes em um mamìfero, para tratar ou prevenir uma infecção microbiana em um mamìfero, para esterilizar um objeto, para preservar um material inorgánico ou orgánico, para tratar uma doença, para reduzir a dose de agente antimicrobiano convencional requerida para tratar uma infecção microbiana e para tratar uma doença de protozoário em um mamìfero, produto combinado, formulação, uso de um produto combinado, composto, e, processo para a preparação do mesmo
TW200600492A (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2414902C1 (ru) Бактерицидная композиция для профилактики и лечения инфекционных заболеваний копыт у животных
AU2021311245A8 (en) Compound for androgen receptor degradation, and pharmaceutical use thereof
AR060089A1 (es) Tratamiento del dolor
PH12022552166A1 (en) Use of compound in preventing and/or treating pathogen infection in animals
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
Adegbeye et al. Potential of silver nanoparticles for veterinary applications in livestock performance and health
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
MX2025005318A (es) Compuesto de cucurbiturilo y uso medico del mismo
MY170991A (en) Dosing regimens of celgosivir for the treatment of dengue
UA49789C2 (uk) Застосування димеру лізоциму як лікарського засобу для інгібування біосинтезу фактора некрозу пухлини, спосіб лікування та профілактики захворювань (варіанти), фармацевтична композиція (варіанти), застосування димеру лізоциму як лікарського засобу для профілактики або лікування сніду
EA202193211A1 (ru) Лечение синуклеопатий
NZ769696A (en) Endoparasitic depsipeptides
BRPI0410576A (pt) composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo
PT1059845E (pt) Composicao fungicida compreendendo uma benzoilfenilureia
UA144735U (uk) Спосіб лікування хвороб органів травлення